Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on Creative Medical (CELZ) to $20 from $26 and keeps a Buy rating on the shares. The company’s clinical programs are on track, the analyst tells investors in a research note. The firm cites financial modeling adjustments for the target cut.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELZ: